Advertisement

Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach

  • Paal JorangerEmail author
  • Arild Nesbakken
  • Halfdan Sorbye
  • Geir Hoff
  • Arne Oshaug
  • Eline Aas
Original Paper

Abstract

New and emerging advances in colorectal cancer (CRC) treatment combined with limited healthcare resources highlight the need for detailed decision-analytic models to evaluate costs, survival and quality-adjusted life years. The objectives of this article were to estimate the expected lifetime treatment cost of CRC for an average 70-year-old patient and to test the applicability and flexibility of a model in predicting survival and costs of changing treatment scenarios. The analyses were based on a validated semi-Markov model using data from a Norwegian observational study (2049 CRC patients) to estimate transition probabilities and the proportion resected. In addition, inputs from the Norwegian Patient Registry, guidelines, literature, and expert opinions were used to estimate resource use. We found that the expected lifetime treatment cost for a 70-year-old CRC patient was €47,300 (CRC stage I €26,630, II €38,130, III €56,800, and IV €69,890). Altered use of palliative chemotherapy would increase the costs by up to 29%. A 5% point reduction in recurrence rate for stages I–III would reduce the costs by 5.3% and increase overall survival by 8.2 months. Given the Norwegian willingness to pay threshold per QALY gained, society’s willingness to pay for interventions that could result in such a reduction was on average €28,540 per CRC patient. The life years gained by CRC treatment were 6.05 years. The overall CRC treatment costs appear to be low compared to the health gain, and the use of palliative chemotherapy can have a major impact on cost. The model was found to be flexible and applicable for estimating the cost and survival of several CRC treatment scenarios.

Keywords

Colorectal cancer Markov model Cost Surgery Chemotherapy Analyse innovations 

Abbreviations

5-FU/FA

Nordic FLv = 5-fluorouracil/folinic acid

CI

Confidence interval

COI

Cost-of-illness

CRC

Colorectal cancer

CrI

Credible interval

EGFR-inh

Epidermal growth factor receptor inhibitors (cetuximab/panitumumab)

FLIRI

A combination of irinotecan and 5-fluorouracil/folinic acid

FLOX

A combination of oxaliplatin and 5-FU/FA

FOBTs

Faecal occult blood tests

HRQoL

Health-related quality of life

LYs

Life years

NPR

National Patient Registry

OUS

Oslo University Hospital

PSA

Probabilistic sensitivity analysis

PS

Patient performance status

QALY

Quality-adjusted life years

WTP

Willingness to pay

JEL Classification

I110 

Notes

Acknowledgements

We acknowledge the Department of Health, Nutrition and Management (HEL), The Faculty of Health Sciences, and Oslo and Akershus University College of Applied Sciences for funding Paal Joranger’s doctorate.

Compliance with ethical standards

Conflict of interest

All authors contributed to the work, are aware of, and agree to the submission. Any other person or body with an interest in the manuscript, such as our funders and employers, are also aware and agreed on the submission. Paal Joranger, Eline Aas, and Arne Oshaug declare no support from any organisation for the submitted work, no financial relationships in the previous 3 years with any organisations that might have an interest in the submitted work, and no other relationships or activities that could appear to have influenced the submitted work. In 2017, Geir Hoff received payment from Amgen Norway for giving a lecture at a medical conference. Halfdan Sorbye received Grants and personal fees from Merck, Roche, and Amgen and personal fees from Sanofi during the study. Arild Nesbakken received funding from Helse Sør-Øst for the clinical studies on colorectal cancer (OUS-Aker series). He is a member of a research group in OUS, which has patents on one diagnostic and two prognostic genetic tests for colorectal cancer. He received payment from Amgen Norway for giving a lecture at a medical conference 2018. Financial support for this study was provided entirely by the authors’ employers, which are listed above. The funding agreements ensured the authors’ independence in designing the study, interpreting the data, and writing and publishing the article. The authors declare that they have no competing interests.

Ethics approval and consent to participate

The observational study from 1993 to 2010, including 2049 patients diagnosed with CRC at Oslo University Hospital, was approved by the Regional Ethics Committee (Norway) for Medical Research (REK approval 1.2005.1629). The study with data collected from the National Patient Register (NPR) was approved by the Regional Ethics Committee (Norway). The reference number is S-02113 (2013/83).

Supplementary material

10198_2019_1130_MOESM1_ESM.pdf (216 kb)
Supplementary material 1 (PDF 216 kb)
10198_2019_1130_MOESM2_ESM.pdf (235 kb)
Supplementary material 2 (PDF 235 kb)
10198_2019_1130_MOESM3_ESM.pdf (316 kb)
Supplementary material 3 (PDF 316 kb)
10198_2019_1130_MOESM4_ESM.pdf (240 kb)
Supplementary material 4 (PDF 239 kb)
10198_2019_1130_MOESM5_ESM.pdf (415 kb)
Supplementary material 5 (PDF 415 kb)

References

  1. 1.
    Jemal, A., Center, M.M., DeSantis, C., Ward, E.M.: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomark. Prev. 19(8), 1893–1907 (2010)CrossRefGoogle Scholar
  2. 2.
    Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J.W.W., Comber, H., et al.: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 49(6), 1374–1403 (2013)CrossRefGoogle Scholar
  3. 3.
    Tarricone, R.: Cost-of-illness analysis. Health Policy 77(1), 51–63 (2006)CrossRefGoogle Scholar
  4. 4.
    Sullivan, S.D., Mauskopf, J.A., Augustovski, F., Jaime Caro, J., Lee, K.M., Minchin, M., et al.: budget impact analysis—principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health 17(1), 5–14 (2014)CrossRefGoogle Scholar
  5. 5.
    Joranger, P., Nesbakken, A., Hoff, G., Sorbye, H., Oshaug, A., Aas, E.: Modeling and validating the cost and clinical pathway of colorectal cancer. Med. Decis. Mak. 35(2), 255–265 (2014).  https://doi.org/10.1177/0272989X14544749 CrossRefGoogle Scholar
  6. 6.
    Meltzer, D.: Accounting for future costs in medical cost-effectiveness analysis. J. Health Econ. 16(1), 33–64 (1997)CrossRefGoogle Scholar
  7. 7.
    Drummond, M., Sculpher, M., Torrance, G., O’Brien, B., Stoddart, G.: Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, Oxford (2005)Google Scholar
  8. 8.
    Sjo, O.H., Lunde, O.C., Nygaard, K., Sandvik, L., Nesbakken, A.: Tumour location is a prognostic factor for survival in colonic cancer patients. Colorectal Dis. 10(1), 33–40 (2008)PubMedGoogle Scholar
  9. 9.
    Nesbakken, A., Nygaard, K., Westerheim, O., Mala, T., Lunde, O.C.: Local recurrence after mesorectal excision for rectal cancer. Eur. J. Surg. Oncol. 28(2), 126–134 (2002)CrossRefGoogle Scholar
  10. 10.
    Aas E (2009) Cost-effectiveness of screening for colorectal cancer with once-only flexible sigmoidoscopy and faecal occult blood test. In: Oslo University, Health Economics Research ProgrammeGoogle Scholar
  11. 11.
    Yabroff, K.R., Lawrence, W.F., Clauser, S., Davis, W.W., Brown, M.L.: Burden of illness in cancer survivors: findings from a population-based national sample. J. Natl. Cancer Inst. 96(17), 1322–1330 (2004).  https://doi.org/10.1093/jnci/djh255 CrossRefPubMedGoogle Scholar
  12. 12.
    Saarni, S.I., Härkänen, T., Sintonen, H., Suvisaari, J., Koskinen, S., Aromaa, A., et al.: The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. Qual. Life Res. 15(8), 1403–1414 (2006)CrossRefGoogle Scholar
  13. 13.
    Do, Health: Economic evaluation of health intervention: a guide. The Norwegian Directorate of Health, Oslo (2012)Google Scholar
  14. 14.
    Mo, Finance: Guid for cost-benefit analysis. The Treasury Department, Oslo (2005)Google Scholar
  15. 15.
    Finance Mo: Principles and requirements for the preparation of socio-economic analyzes. Ministry of Finance, Oslo (2014)Google Scholar
  16. 16.
    Razenberg, L.G.E.M., Creemers, G.-J., Beerepoot, L.V., Vos, A.H., van de Wouw, A.J., Maas, H.A.A.M., et al.: Age-related systemic treatment and survival of patients with metachronous metastases from colorectal cancer. Acta Oncol. 55(12), 1443–1449 (2016)CrossRefGoogle Scholar
  17. 17.
    Sorbye, H., Pfeiffer, P., Cavalli-Björkman, N., Qvortrup, C., Holsen, M.H., Wentzel-Larsen, T., et al.: Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer 115(20), 4679–4687 (2009)CrossRefGoogle Scholar
  18. 18.
    Scholefield, J.H., Moss, S.M., Mangham, C.M., Whynes, D.K., Hardcastle, J.D.: Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut 61(7), 1036–1040 (2012)CrossRefGoogle Scholar
  19. 19.
    RCPH (2007) Screening for colorectal cancer in Vejle and Copenhagen County: Research Centre for Prevention and Health (RCPH)Google Scholar
  20. 20.
    Tappenden, P., Chilcott, J., Eggington, S., Sakai, H., Karnon, J., Patnick, J.: Option appraisal of population-based colorectal cancer screening programmes in England. Gut 56(5), 677–684 (2007)CrossRefGoogle Scholar
  21. 21.
    Frazier, A.L., Colditz, G.A., Fuchs, C.S., Kuntz, K.M.: Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 284(15), 1954–1961 (2000)CrossRefGoogle Scholar
  22. 22.
    Tappenden, P., Eggington, S., Nixon, R., Chilcott, J., Sakai, H., Karnon, J.: Colorectal cancer screening options appraisal: cost-effectiveness, cost-utility and resource impact of alternative screening options for colorectal cancer. University of Sheffild, Sheffild (2004)Google Scholar
  23. 23.
    Ladabaum, U., Phillips, K.A.: Colorectal cancer screening: differential costs for younger versus older Americans. Am. J. Prev. Med. 30(5), 378–384 (2006)CrossRefGoogle Scholar
  24. 24.
    Brown, M.L., Riley, G.F., Potosky, A.L., Etzioni, R.D.: Obtaining long-term disease specific costs of care: application to medicare enrollees diagnosed with colorectal cancer. Med. Care 37(12), 1249–1259 (1999)CrossRefGoogle Scholar
  25. 25.
    Yabroff, K.R., Borowski, L., Lipscomb, J.: Economic studies in colorectal cancer: challenges in measuring and comparing costs. JNCI Monogr. 2013(46), 62–78 (2013)CrossRefGoogle Scholar
  26. 26.
    Tilson, L., Sharp, L., Usher, C., Walsh, C., Whyte, S., O’Ceilleachair, A., et al.: Cost of care for colorectal cancer in Ireland: a health care payer perspective. Eur. J. Health Econ. 13(4), 511–524 (2012)CrossRefGoogle Scholar
  27. 27.
    Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J.H., et al.: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27(8), 1386–1422 (2016).  https://doi.org/10.1093/annonc/mdw235 CrossRefPubMedGoogle Scholar
  28. 28.
    Tejpar, S., Stintzing, S., Ciardiello, F., et al.: Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the crystal and fire-3 trials. JAMA Oncol. 3(2), 194–201 (2017)CrossRefGoogle Scholar
  29. 29.
    Norderhaug, I.T.H.: Pasientvolum og kvalitet ved koloncancerkirurgi. Nasjonalt kunnskapssenter for helsetjenesten, Oslo (2009)Google Scholar
  30. 30.
    Meyerhardt, J.A., Giovannucci, E.L., Holmes, M.D., Chan, A.T., Chan, J.A., Colditz, G.A., et al.: Physical activity and survival after colorectal cancer diagnosis. J. Clin. Oncol. 24(22), 3527–3534 (2006)CrossRefGoogle Scholar
  31. 31.
    Meyerhardt, J.A., Heseltine, D., Niedzwiecki, D., Hollis, D., Saltz, L.B., Mayer, R.J., et al.: Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J. Clin. Oncol. 24(22), 3535–3541 (2006)CrossRefGoogle Scholar
  32. 32.
    Meyerhardt, J.A., Giovannucci, E.L., Ogino, S., Kirkner, G.J., Chan, A.T., Willett, W., et al.: Physical activity and male colorectal cancer survival. Arch. Intern. Med. 169(22), 2102–2108 (2009)CrossRefGoogle Scholar
  33. 33.
    Lynch, B.M., Cerin, E., Owen, N., Aitken, J.F.: Associations of leisure-time physical activity with quality of life in a large, population-based sample of colorectal cancer survivors. Cancer Causes Control 18(7), 735–742 (2007)CrossRefGoogle Scholar
  34. 34.
    Haydon, A.M., MacInnis, R.J., English, D.R., Giles, G.G.: Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut 55(1), 62–67 (2006)CrossRefGoogle Scholar
  35. 35.
    Meyerhardt, J.A., Niedzwiecki, D., Hollis, D., Saltz, L.B., Hu, F.B., Mayer, R.J., et al.: Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA 298(7), 754–764 (2007)CrossRefGoogle Scholar
  36. 36.
    Huxley, R.R., Ansary-Moghaddam, A., Clifton, P., Czernichow, S., Parr, C.L., Woodward, M.: The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int. J. Cancer 125(1), 171–180 (2009)CrossRefGoogle Scholar
  37. 37.
    Rock, C.L., Doyle, C., Demark-Wahnefried, W., Meyerhardt, J., Courneya, K.S., Schwartz, A.L., et al.: Nutrition and physical activity guidelines for cancer survivors. CA Cancer J. Clin. 62(4), 242–274 (2012)CrossRefGoogle Scholar
  38. 38.
    Ravasco, P., Monteiro-Grillo, I., Camilo, M.: Individualized nutrition intervention is of major benefit to colorectal cancer patients: long-term follow-up of a randomized controlled trial of nutritional therapy. Am. J. Clin. Nutr. 96(6), 1346–1353 (2012)CrossRefGoogle Scholar
  39. 39.
    Hamers, P., Bos, A.C.R.K., May, A.M., Punt, C.J.A., Koopman, M., Vink, G.R.: Recent changes in overall survival of real-life stage IV colorectal cancer patients. J. Clin. Oncol. 37(15_suppl), 3522 (2019)CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Norwegian University of Life SciencesÅsNorway
  2. 2.Faculty of Health SciencesOsloMet-Oslo Metropolitan UniversityOsloNorway
  3. 3.Department of Gastrointestinal SurgeryOslo University HospitalOsloNorway
  4. 4.K.G. Jebsen Colorectal Cancer Research Centre, Oslo University HospitalOsloNorway
  5. 5.Faculty of MedicineUniversity of OsloOsloNorway
  6. 6.Department of Oncology and Department of Clinical ScienceHaukeland University HospitalBergenNorway
  7. 7.University of BergenBergenNorway
  8. 8.Telemark HospitalSkienNorway
  9. 9.The Cancer Registry of NorwayOsloNorway
  10. 10.University of OsloOsloNorway
  11. 11.Institute of Health and Society, Department of Health Management and Health EconomicsUniversity of OsloOsloNorway

Personalised recommendations